Fingerprint
Dive into the research topics of 'Intravitreal Nesvacumab (Anti-Angiopoietin-2) Plus Aflibercept in Neovascular AMD: Phase 2 ONYX Randomized Trial'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Intravitreal Nesvacumab (Anti-Angiopoietin-2) Plus Aflibercept in Neovascular AMD: Phase 2 ONYX Randomized Trial
Jeffrey S. Heier, Allen C. Ho, David S. Boyer, Karl Csaky, Robert Vitti, Lorah Perlee, Karen W. Chu, Friedrich Asmus, Sergio Leal, Oliver Zeitz, Yenchieh Cheng, Thomas Schmelter, David M. Brown
Research output: Contribution to journal › Article › peer-review
5
Scopus
citations